Activation of endoplasmic reticulum stress is involved in the activity of icariin against human lung adenocarcinoma cells

In this study, we investigated the anticancer activity of icariin (ICA) against human lung adenocarcinoma cells in vitro and in vivo and explored the role of endoplasmic reticulum (ER) stress (ERS) signaling in this process. ICA treatment resulted in a dose- and time-dependent decrease in the viability of human lung adenocarcinoma A549 cells. Additionally, ICA exhibited potent anticancer activity, as evidenced by reductions in A549 cell adhesion, migration and intracellular glutathione (GSH) levels and increases in the apoptotic index, Caspase 3 activity, and reactive oxygen species. Furthermore, ICA treatment increased the expression of ERS-related molecules (p-PERK, ATF6, GRP78, p-eIF2α, and CHOP), up-regulated the apoptosis-related protein PUMA and down-regulated the anti-apoptosis-related protein Bcl2. The down-regulation of ERS signaling using PERK siRNA desensitized lung adenocarcinoma cells to ICA treatment, whereas the up-regulation of ERS signaling using thapsigargin (THA) sensitized lung adenocarcinoma cells to ICA treatment. Additionally, ICA inhibited the growth of human lung adenocarcinoma A549 cell xenografts by increasing the expression of ERS-related molecules (p-PERK and CHOP), up-regulating PUMA, and down-regulating Bcl2. These data indicate that ICA is a potential inhibitor of lung adenocarcinoma cell growth by targeting ERS signaling and suggest that the activation of ERS signaling may represent a novel therapeutic intervention for lung adenocarcinom...
Source: Apoptosis - Category: Molecular Biology Source Type: research

Related Links:

Publication date: Available online 29 May 2020Source: International Journal of Surgery Case ReportsAuthor(s): Kaoru Wada, Hirofumi Tazawa, Toshiaki Komo, Naoto Hadano, Takashi Onoe, Takeshi Sudo, Yosuke Shimizu, Kazuya Kuraoka, Takahisa Suzuki, Hirotaka Tashiro
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
ConclusionsPatients who receive neoadjuvant chemotherapy for liver metastasis surgery have a greater splenic volume increase, which correlates with NAFLD and a lower survival.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Locally Advanced Rectal Carcinoma;   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v8;   Stage IIA Rectal Cancer AJCC v8;   Stage IIB Rectal Cancer AJCC v8;   Stage IIC Rectal Cancer AJCC v8;   Stage III Rectal Cancer AJCC v8;   Stage IIIA Rectal Can cer AJCC v8;   Stage IIIB Rectal Cancer AJCC v8;   Stage IIIC Rectal Cancer AJCC v8 Inte...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Esophageal Adenocarcinoma;   Barrett Esophagus Intervention:   Behavioral: Survey Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Locally Advanced Rectal Carcinoma;   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v8;   Stage IIA Rectal Cancer AJCC v8;   Stage IIB Rectal Cancer AJCC v8;   Stage IIC Rectal Cancer AJCC v8;   Stage III Rectal Cancer AJCC v8;   Stage IIIA Rectal Can cer AJCC v8;   Stage IIIB Rectal Cancer AJCC v8;   Stage IIIC Rectal Cancer AJCC v8 Inte...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Esophageal Adenocarcinoma;   Barrett Esophagus Intervention:   Behavioral: Survey Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 28 May 2020Source: Pathology - Research and PracticeAuthor(s): Yang Ma, Yun Du, Rui Wang, Xiaokun Ji, Juan Wu, Ying Liu, Xiao Guo, Yan Zhang
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa ® (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO2 0 Virtual Scientific Programme, on 29 May 2020.“These data further support Alecensa as the standard of care for people with metastatic AL...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
(NRG Oncology) Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Advanced pancreatic ductal adenocarcinoma (aPDAC) patients have a lifetime all type thromboembolic event (ATTE) rate of 25 –35%. Efficacy and safety of increased dose primary thromboprophylaxis (IDPTP) with low...
Source: Thrombosis Journal - Category: Hematology Authors: Tags: Research Source Type: research
More News: Adenocarcinoma | Molecular Biology | Study